AS-OCT Guided Treatment Of Diffuse Conjunctival Squamous Cell Carcinoma With Resection, Amniotic Membrane Graft And Topical Mitomycin C

This article was published in the following Dove Press journal:
Clinical Ophthalmology

Tarek Roshdy Elhamaky
Ahmed Mohammed Elbarky
Department of Ophthalmology, Benha Faculty of Medicine, Benha University, Benha, Egypt

Purpose: To evaluate the efficacy of combined limited surgical resection, amniotic membrane graft and topical mitomycin C in treatment of diffuse conjunctival squamous cell carcinoma (CSCC) diagnosed and followed up by anterior segment optical coherence tomography (AS-OCT).

Subjects and methods: A prospective study was performed on 24 eyes with diffuse CSCC. Fifteen eyes underwent lesion limited resection followed by postoperative topical mitomycin C 0.04% eye drop (MMC group) while nine eyes underwent complete excision and cryotherapy (no MMC group). Amniotic membrane graft was applied in all cases. The diagnosis was based on clinical and AS-OCT specific criteria of CSCC and was confirmed by histopathological results.

Results: The study population was similar between the two groups. Mean postoperative follow-up was 27.1±4.1 months. The mean extent of the limbal involvement was 7.0±0.7 and 7.25±0.6 clock hours in MMC and no MMC groups, respectively. The mean size of conjunctival defect after tumor excision in MMC group (60.8±9.2 mm$^2$) was significantly lower than in no MMC group (92.4±17.3 mm$^2$). Histopathological diagnosis revealed invasive SCC in all specimens. The mean preoperative conjunctival epithelial thickness decreased significantly in both groups at 2-year follow-up. It decreased from 267±24.2 and 256±19.1 μm preoperatively to 56.7±11.6 and 60.4±9.6 μm at 2-year follow-up in MMC and no MMC groups, respectively. The mean number of MMC treatment cycles was 2.1±0.85 cycles. Recurrence was recorded in zero (0%) and 1 (11%) patients at 2-year follow-up in MMC and no MMC groups, respectively.

Conclusion: The treatment of diffuse CSCC with AS-OCT guided combined therapy includes limited surgical resection, AMG, and postoperative topical MMC, achieves a complete tumor resolution and good functional and cosmetic outcomes minimizing the burden of surgery, and improves postoperative patient comfort in our study cohort.

Keywords: diffuse, conjunctival squamous cell carcinoma, mitomycin C, AS-OCT, amniotic membrane graft

Introduction
Ocular surface squamous neoplasia (OSSN) is the most common malignant tumor of the ocular surface with a high incidence in men between 50 and 75 years of age and at latitude of 16 degree south.1,2
Conjunctival squamous cell carcinoma (CSCC) has been causally related to UV-B radiation, human papilloma virus, cigarette smoking, immunosuppressant, and HIV infection.\(^3\)

CSCC involves the conjunctival interpalpebral zone in a diffuse, nodular, papilliform, gelatinous, leukoplakic or invasive fashion.\(^4\)

Tumor sizes were divided into small, medium, and large tumors. Large and diffuse tumors were defined as those more than 5 limbal clock hours or more than 8 mm in largest diameter.\(^5,6\)

The mainstays for the diagnosis of OSSN encompass the spectrum of conjunctival and corneal intraepithelial neoplasia and CSCC remains histopathologic evaluation after a surgical excision.\(^7\)

Anterior segment optical coherent tomography (AS-OCT) can yield an optical biopsy of tissue, helping in the diagnosis and follow-up of ocular surface lesions. The appearance of OSSN on HR-OCT is a thickened, hyper-reflective epithelium, and an abrupt transition between the normal and affected epithelium.\(^8,9\)

CSCC is considered a low-grade malignancy. Recurrence is generally higher for severe grades of OSSN and depends also on the adequacy of malignancy free margins at the primary excision. Ascertaining of tumor edges and deep margins are difficult.\(^10–12\)

The treatment options for conjunctival epithelial malignancies include tumor removal with or without cryotherapy, radiotherapy, electron-based external beam radiation therapy, or topical chemotherapy (i.e., interferon, mitomycin C, or 5-fluorouracil). Primary chemotherapy has also been used as an isolated therapy. Larger, multifocal, or aggressive tumors have required combinations of all previous lines of therapy.\(^13–15\)

Mitomycin C (MMC) has a significant anti-tumor activity and is effective for treatment of superficial OSSN allowing the treatment of the entire ocular surface including the conjunctival fornices, destroy subclinical disease and prevent new tumors growth elsewhere on the ocular surface.\(^14,16\)

Amniotic membrane graft (AMG) has been proven to be an effective technique for the management of ocular surface reconstructions following the excision of ocular surface squamous tumors.\(^17,18\)

Diffuse CSCC has been considered as a therapeutic challenge, despite the available therapeutic modalities. In this cohort, we carried out a prospective analysis to assess the outcomes of diffuse CSCC management. This treatment regimen included surgical resection accompanied with AMG then was followed by postoperative topical MMC 0.04% course. Limited surgical resection of conjunctiva lesion was followed in this cohort to minimize tissue loss.

### Subjects And Methods

#### Patient Selection And Data Collection

Twenty-four cases of diffuse CSCC were included in this nonrandomized prospective study. Diffuse CSCC was defined as a lesion spread more than five clock hours in limbal extent or more than 8 mm in largest diameter.\(^5,6\) Fifteen patients underwent amniotic membrane graft after limited resection of diffuse CSCC followed by postoperative topical mitomycin C 0.04% eye drop (MMC group). Nine patients underwent amniotic membrane graft after excision of diffuse CSCC (no MMC group). One surgeon (T.E.) performed all surgeries.

Complete ophthalmic examinations, anterior segment slit-lamp photography, AS-OCT was performed preoperatively and at all subsequent follow-up visits. Data collection included age, sex, laterality, visual acuity, neoplasm characters, AM graft size, histopathological results, recurrence, complications, surface healing, patient comfort (according to the Ocular Surface Disease Index (OSDI) questionnaire) and cosmetic appearance (according to the grades of conjunctival injection as none: 0, mild: 1, moderate: 2, and severe: 3).\(^18\)

Exclusion criteria were lesions with localized spread (less than five clock hours in limbal extent) and primary chemotherapy treatment.

### Imaging

Slit-lamp photography: anterior segment digital images were taken by slit-lamp cam (5.0, integrated and 5 megapixels) attached to the slit-lamp microscope (Zeiss 220 SL, Carl Zeiss Meditec AG, Jena, Germany).

AS-OCT: Anterior Segment 5 Line Raster scanning protocol of Cirrus HD-OCT 5000 system (Carl Zeiss Meditec AG, Jena, Germany) was used in ocular surface lesions imaging. The epithelial thickness of the tumor was measured on its greatest dimension by the distance-measuring tool. Hyper-reflectivity and hypo-reflectivity of conjunctival epithelium and subepithelial component were defined as increased whiteness and darkness compared to normal subjects, respectively.\(^9\)

The appearance of CSCC on HR-OCT is a thickened, hyper-reflective epithelium and an abrupt transition between the normal and affected epithelium.\(^8,9\)
The diagnosis was based on clinical and AS-OCT specific criteria of CSSC and was confirmed by histopathological results. Staging of tumors was done according to AJCC classification.

Treatment

Surgery

In MMC group, clinically apparent healthy conjunctiva was marked. The corneal and conjunctival lesions were excised after corneal epithelial scraping. In no MMC group, the corneal and conjunctival lesions excision involves 2-mm margin of normal-looking epithelium was done, then double freeze-thaw cryotherapy was applied to all surgical margins and allowed to thaw. A “no-touch” excision technique was used in both groups.19,20

Excised specimens were sent for histopathologic diagnosis. The amniotic membrane graft (Amnio Tek [3*3 cm]; ISP Surgical) was cut to fit the size of conjunctival defect then was secure with the epithelial side facing up and attached to the sclera and conjunctiva using fibrin glue (Tisseel®, Baxter Inc., Deerfield, IL, USA). Eye pressure patch was applied for 24 hrs to provide a tight graft adherence.

Postoperatively,

- Topical mitomycin C 0.04% eye drop is prescribed 4 times daily per treatment cycle (1 cycle=[1 week on & 1 week off) in MMC group. The treatment cycles were repeated if any tumor persistence or recurrence detected clinically and on AS-OCT images.
- Tobramycin–dexamethasone eye drops four times daily on a tapered regimen and a lubricating eye drop were prescribed for a month.

Follow-up visits were performed weekly during the 1st month following the treatment, monthly for 1st year, then twice yearly.

The Primary Outcome Measure

The recurrence of tumor which was detected clinically and/or on AS-OCT at 2-year follow-up while the secondary outcomes included cosmetic appearance and surgical or MMC-related complications.

Study Approval

The study was approved by the local ethics committee of advanced center for daycare surgery, Abu Dhabi, UAE. This study has followed the Tenets of the Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. ClinicalTrials.gov ID is NCT03515954

Statistical Analysis

Variables were revealed as a mean±standard deviation or percentage. Paired Student’s t-test was used for variables analysis. A P-value less than 0.05 was considered statistically significant. Statistical analysis was performed using Windows SPSS software version 16.0 (SPSS, Inc., Chicago, IL) (Figures 1 and 2).

Results

This is a prospective study included 24 eyes of 24 patients. Mean postoperative follow-up was 27.1±4.1 (range, 19–31) months. The study population was similar between the two groups; the mean age of patients was 57.4±12.6 years with 11 males (73.3%) and 4 females (26.7%) in MMC group and 60.4±3.8 years with 6 males (66.7%) and 3 females (33.3%) in no MMC group. One patient showed an atypical presentation of CSCC; the patient was young (35 years old) and HIV negative.

The mean extent of the limbal involvement was 7.0±0.7 and 7.25±0.6 clock hours in MMC group and no MMC group, respectively. According to AJCC classification, there were 7 (46.7%) T2 tumors and 8 (53.3%) T3 tumors in MMC group and 3 (22.2%) T2 tumors and 6 (77.8%) T3 tumors in no MMC group. The mean size of conjunctival defect after tumor excision in MMC group (60.8±9.2 mm$^2$) was significantly lower than in no MMC group (92.4±17.3mm$^2$) (P value <0.0001). Mean operative time was 38.6±2.7 and 39.8±3.2 mins in MMC group and no MMC group, respectively.

Histopathological diagnosis revealed invasive CSCC in all specimens. Severe dysplasia was associated with invasive SCC in 3 patients in MMC group. Involvement of the excision margin was reported in 6 (40%) and 1 (11%) specimens in MMC and no MMC groups, respectively.

BCVA changed insignificantly from 0.3±0.25 and 0.32 ±0.18 log MAR preoperatively to 0.25±0.17 and 0.27±0.17 log MAR at 2-year follow-up in MMC group and no MMC group, respectively.

The mean OSDI score changed insignificantly from 10.8±0.25 and 10.4±2.9 preoperatively to 10.0±3.1 and 0.27±3.5 at 2-year follow-up in MMC group and no MMC group, respectively.
According to conjunctival injection grades, there were 12 (80%) grade 0 and 3 (20%) grade 1 in MMC group and 6 (75%) grade 0 and 2 (25%) grade 1 in no MMC group.

The mean preoperative conjunctival epithelial thickness decreased significantly in both groups at 2-year follow-up. It decreased from 267±24.2 & 256±19.1 μm preoperatively to 56.7±11.6 & 60.4±9.6 μm at 2-year follow-up in MMC group and no MMC group, respectively (P value <0.0001). AS-OCT images showed characteristic appearance of CSCC in the form of a thickened, hyper-reflective epithelium and an abrupt transition between the normal and affected epithelium which correlate with histopathology results of primary, postoperative subclinical disease, and recurrent cases. The mean number of MMC treatment cycles was 2.1±0.85 cycles.

Recurrence was recorded in zero (0%) and 1 (11%) patients at 2-year follow-up in MMC and no MMC groups, respectively (Table 1).

In MMC group, 3 patients suffered from epiphora, which was relieved after nasolacrimal syringing and conjunctival hyperemia and punctuate keratopathy but disappeared on cessation topical MMC. No major operative or MMC-related complications were recorded.

Discussion

We conducted a prospective study on 24 eyes with diffuse CSCC. Fifteen eyes underwent combined surgical and topical chemotherapy treatment lines starting with lesion resection followed by postoperative topical mitomycin C 0.04% eye drop (MMC group) while nine eyes underwent complete excision and cryotherapy (no MMC group). The
Figure 2. Case 2 (MMC group): a 56-year-old male with OSSN of the left eye. **A–C**: slit-lamp photographs: **(A)** preoperative shows a diffuse papillary lesion on the temporal conjunctiva with conjunctival fornices extension. **(B)** 1-week post-operative shows congested ocular surface which was reconstructed with AMG. **(C)** 2-year follow-up shows a complete resolution of the lesion. **(D, E)** AS-OCT images: **(D)** preoperative shows a thickened and hyper-reflective epithelium (red arrow). **(E)** 2-year follow-up: in the area of the previous lesion shows back to a normal thin epithelial thickness and appearance (red arrow). **(F–I)** Histopathological specimen [H&E, low power (F, G) & high power (H, I)]; sections reveal fibrovascular tissue with many congested blood vessels lined by stratified squamous epithelium. In some areas, there is atypia throughout the full thickness of epithelium with individual tumor cells and nests extending into underlying stroma. The tumor cells (yellow arrow) show eosinophilic cytoplasm, intercellular bridges and atypical nuclei with prominent nucleoli and coarse chromatin. Frequent mitotic figures, including atypical mitoses, are also seen. This is consistent with invasive squamous cell carcinoma; moderately differentiated and adjacent area shows moderate to severe dysplasia and intraepithelial neoplasia (carcinoma-in-situ).
conjunctival defect was covered with AMT secured by fibrin glue. The diagnosis and treatment of CSCC was monitored by AS-OCT.

The study results were similar between the two groups except the size of conjunctival defect after tumor excision was significantly lower in MMC group than in no MMC group and we think that minimized the burden of surgery on ocular surface and improved postoperative patient comfortless. The recurrence rate was 0% and 11% in MMC and no MMC groups, respectively.

Early diagnosis and proper management of OSSN can prevent significant ocular morbidity. The treatment of larger CSCC is a challenging task for all forms of therapy. A perfect treatment of OSSN should achieve complete tumor eradication, proper reconstruction of the lost tissue and achieving good functional and cosmetic appearance.

The primary surgical resection with lesion-free margins is the mainstay of treatment for OSSN providing advantages of surgical debulking, confirming a definitive histopathological diagnosis and exclude life-threatening invasive carcinoma.

The use of topical or intralesional chemotherapeutic agents such as mitomycin C or IFNa2b has become widespread. However, in the review of the literature, it appears that most centers selectively treat large (>8 mm in diameter) tumors with surgery and adjuvant cryotherapy or chemotherapy.

The lack of prior surgical debulking resulted in the higher persistence and recurrence rates noted in cases with diffuse disease. On the other hand, surgical excision of diffuse conjunctival lesions is potentially hazardous due to the risk of limbal stem cell failure and marked tissue loss in the attempt for achieving clear surgical margins. Moreover, the recurrence rate is still high, ranging from 15% to 52%, with the sole primary excision even with lesion-free margins.

AS-OCT is a useful adjunctive tool for the diagnosis and management of ocular surface lesions. AS-OCT is a noninvasive technique, able to detect subclinical disease, monitoring for OSSN resolution during medical treatment and prevent the premature termination of topical therapy. Disadvantage of AS-OCT concerning OSSN is the inability to exclude invasive disease and assess intracellular characteristics. Besides, the fornix and caruncle lesions are difficult to be scanned.

In our cohort, AS-OCT showed a characteristic appearance of CSCC in all cases helping not only the diagnosis of primary and postoperative subclinical, persistent or recurrent cases, but also monitoring postoperative topical therapy. AS-OCT is a very helpful and adjunctive tool in diagnosis and management of CSCC but the mainstay for the diagnosis of CSCC remains histopathologic evaluation.

Topical chemotherapy such as MMC, 5FU, and IFN a2b has been used as treatment for OSSN. Some case series of large CSCC showed complete tumor resolution with the use of sole topical chemotherapy.

On the other hand, some publications reported that not only the efficacy of isolated chemotherapy in large or invasive OSSN is low but also it is contraindicated for invasive tumors explaining that, topical agents unlikely penetrate to the required level to reach the invasive cells.

### Table 1 Summary Of Demographic And Clinical Results

| Variable                                | Result (Mean±SD Or Total (%)) |
|-----------------------------------------|-------------------------------|
| Age (years):                            |                               |
| • MMC group                             | 57.4±12.6                     |
| • No MMC group                          | 60.4±3.8                      |
| Gender, male & female (%)               |                               |
| • MMC group                             | 11 (73.3%) & 4 (26.7%)        |
| • No MMC group                          | 6 (66.7%) & 3 (33.3%)         |
| Follow-up period (months):              | 27.1±4.1 (range, 19–31)       |
| Extent of the limbal involvement (clock hours): |                       |
| • MMC group                             | 7.0±0.7                       |
| • No MMC group                          | 7.25±0.6                      |
| Operative time (minutes):               |                               |
| • MMC group                             | 38.6±2.7                      |
| • No MMC group                          | 39.8±3.2                      |
| Conjunctival defects (mm²):*            |                               |
| • MMC group                             | 63.6±19.3                     |
| • No MMC group                          | 92.4±17.3                     |
| BCVA preoperative & 2-year follow-up (log MAR): |                |
| • MMC group                             | 0.3±0.25 & 0.25±0.17          |
| • No MMC group                          | 0.32±0.18 & 0.27±0.17         |
| The conjunctival epithelial thickness preoperative & 2-year follow-up (μm):* |                   |
| • MMC group                             | 267±24.2 & 56.7±11.6          |
| • No MMC group                          | 256±19.1 & 60.4±9.6           |
| Number of MMC treatment cycle (cycles)  | 2.1±0.85                      |
| Recurrence, total (%)                   |                               |
| • MMC group                             | Zero (0%)                     |
| • No MMC group                          | 1(11%)                        |

Note: A significant different at P value <0.05. Abbreviations: SD, standard deviation; MMC, mitomycin C; CSCC, conjunctival squamous cell carcinoma.
Topical chemotherapy needs long treatment duration and patient compliance. IFNa2b shows favorable outcomes in the treatment of primary and recurrent OSSN but it requires a longer duration of treatment than is required with MMC, which may be a disadvantage.\textsuperscript{23,35}

Although zero recurrence rate with sole chemotherapy in Shields et al report, they recommended that extensive tumors may be managed by topical mitomycin C following appropriate biopsy. In Albert et al’s study, which carried out excisional biopsy and adjunctive cryotherapy for OSSN treatment, nonetheless, the majority of incompletely excised OSSN (25/28) showed no recurrence. Our study and Bello et al case report of giant OSSN carried out the same therapeutic combination by performing an early tumor excision and followed by topical treatment with MMC and IFNa2b, respectively (Table 2).\textsuperscript{5,6,14,20,22–24,28,35,37–39}

Reports of successful treatment of giant OSSN with topical treatment may give a false sense of clinical effectiveness of topical therapies for all degrees of invasive disease. Until the depth at which topical therapies lose their anti-neoplastic effectiveness is known, treating CSCC with topical agents alone must be cautious.\textsuperscript{40}

The conjunctival defect created by excision of CSCC was repaired with primary closure techniques, but large one often required tissue replacement. The use of AMG has improved the outcomes for CSCC surgery, as a biological bandage

### Table 2 Previous Reports On Treatment For Diffuse CSCC

| Author(s)/Year | Surgical Technique | Recurrence (%) | Number Of Eyes | Follow-Up Months |
|----------------|--------------------|----------------|----------------|------------------|
| Shield et al\textsuperscript{13}/2002 | Topical mitomycin C 0.04% four times daily for 7 days followed by 7 days off (repeated until completely regressed using slit-lamp biomicroscopy) | 0% | 10 extensive CSCC | 6–50 |
| Frucht-Pery et al\textsuperscript{17}/2002 | (Topical MMC, 0.02% or 0.04%, four times daily for 14 days per course/2-3 courses) Histologic evaluation was done 1 month after the final treatment | 0% | 5 incompletely excised CSCC. | 18 - 37 |
| Khokhar et al\textsuperscript{19}/2002 | Excision+cryotherapy+0.02% MMC at the time of surgery. | 0% | 5 recurrent OSSN | More than 12 |
| Shields et al\textsuperscript{13}/2005 | Chemoreduction: MMC (0.04% four times a day/week on –week off per cycle/2-3 cycles until no further regression or patient intolerance or toxicity)+ surgical resection of the residua (2 weeks after cessation of MMC) | 0% | 3 extensive thick CSCC | N/A |
| Gupta, Muecke\textsuperscript{3}/2010 | Primary topical MMC (0.04% four times a day/week on –week off per cycle/2-3 cycles) ● 10% (one case) with partial Regression ● 20% (two) with recurrence. | | 10 diffuse CSCC | 5.8–119.8 |
| Kim et al\textsuperscript{19}/2012 | Topical and/or intralesional IFN-\(\alpha\)2b ● Complete control in 72% ● Reduction in size in 28% | | 18 giant OSSN | Median follow-up of 11 |
| Palamar et al\textsuperscript{4}/2014 | Excision+AMG secured by suture 0% (good cosmetic and functional) | | 10 OSSN | 13–75 |
| Albert et al\textsuperscript{22}/2015 | Excision+cryotherapy±AMG 7% (3/43; all from +ve margin group) | | 28 incomplete excision OSSN | 18.4–44.3 |
| Joag et al\textsuperscript{9}/2016 | Primary topical 5FU 11% (4 patients) | | 44 OSSN | 2–77 |
| Bello et al\textsuperscript{23}/2016 | A surgical excision without safety margins +IFNa2b. 0% | | Case study of giant OSSN | 24 |
| Hanada et al\textsuperscript{21}/2017 | Excision +0.04% MMC treatment for the exposed sclera+AMG 25% | | 8 | 36–78 |

(Continued)
covers underlying ocular structures, facilitates healing. Many publications have reported the successful use of AMG in the reconstruction of conjunctival defects following different types of conjunctival tumors and mentioned little postoperative complication as symblepharon, pyogenic granuloma, and fibrosis. Using fibrin glue shortens the operating time and promotes postoperative patient comfort.22,39,41–43

Immunoreduction with interferons or topical MMC chemoreduction allow complete excision of giant or diffuse conjunctival SCC not involving orbit.24,44

Based on previous discussion, we believe that CSSC management notably diffuse type is an enigma and challenge for ocular surgeons. All lines of therapy either isolated or combined have their advantages and disadvantages.

In our cohort, we started with limited surgical resection of the lesion followed by topical treatment with MMC. An early surgical excision gave the advantage of confirmation of diagnosis and lesion debulking to decrease recurrence and persistence of tumor with the minimal tissue loss. Limited excision had advantage of minimal tissue loss but carried the risk of incomplete excision and tumor persistence.

We think that postoperative topical chemotherapy; as MMC can overcome the possibility of incomplete lesion excision and give advantage of assuring tumor resolution, besides, manage any subtle residual epithelial malignancy. AMG application helps in ocular surface reconstruction attains a good cosmetic appearance.

Prospective study compares current approach (limited excision followed by adjuvant MMC chemotherapy) and chemoreduction followed by surgical excision would answer the question of superiority of either technique in the treatment of diffuse and giant CSSC. Limitations of this study include a relatively small cohort size.

**Table 2 (Continued).**

| Author(s)/Year | Surgical Technique | Recurrence (%) | Number Of Eyes | Follow-Up Months |
|----------------|--------------------|----------------|----------------|------------------|
| Joag et al29/2016 | 5-Fluorouracil 1% 4 times daily for 1 week followed by a drug holiday of 3 weeks | 18% | 44 OSSN | The median follow-up 10 months (range, 2–77 months) |
| Parrozzani et al26/2017 | 1% 5-FU four times a day for 4 weeks Adjunctive courses were administered after 1 month of chemotherapy-free interval. | 17% (effective treatment for patients affected by preinvasive OSSN and for a limited proportion (50%) of invasive OSSN). | 41 | Mean follow-up was 105±32 months (range 60–171 months) |
| Chaugule et al25/2018 | IFN α2b and/or 5 1% SFU. Exfoliative biopsy to confirm the diagnosis | 0% | 10 giant OSSN | 3–25 |
| Meel et al44/2018. | Immunoreduction(intraorbital IFNα2b of 3 injections at week interval)+ A wide surgical excision and cryotherapy and intraoperative 0.04% MMC +Topical interferon (1 million IU/mL – four times a day) drops 3 months after surgery. | 0% | Case report of locally advanced orbito-conjunctival | 24 months |
| Current study | Modified excision+AMG+MMC (0.04% four times a day/week on --week off per cycle)(repeated until completely regressed clinically using slit-lamp biomicroscopy and AS-OCT) | 0% | 15 diffuse CSCC | 19–31 |

Abbreviations: OSSN, ocular surface squamous cell neoplasia; CSCC, conjunctival squamous cell carcinoma; AMT, amniotic membrane transplant; MMC, mitomycin C; IFNα2b, interferon alpha 2b; SFU, 5 fluorouracil; AS-OCT, anterior segment optical coherent tomography.
Abbreviations
CSCC, conjunctival squamous cell carcinoma; OSSN, ocular surface squamous neoplasia; MMC, mitomycin C; AS-OCT, anterior segment optical coherent tomography; AMG, amniotic membrane graft; 5FU, 5 Fluorouracil; INF a2b, interferon alpha 2b; H&E, hematoxylin-eosin; HIV, human immunodeficiency virus; AJCC, American Joint Committee on Cancer; OSDI, Ocular Surface Disease Index.

Data Availability Statement
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request without end date.

Acknowledgment
Part of this study was presented by Dr Tarek Roshdy Elhamaky as free paper abstract in 38th ESOPRS annual meeting, Hamburg, Germany (11–14 September 2019).

Disclosure
No financial support was received for this submission. No substantial contribution was provided for this submission. The authors declare no conflicts of interest in this work.

References
1. Lee GA, Hiest LW. Ocular surface squamous neoplasia. Surv Ophthalmol. 1995;39(6):420–450. doi:10.1016/S0039-6257(05)80054-2
2. Gichuhi S, Ohnuma SI, Sagoo MS, et al. Pathophysiology of ocular surface squamous neoplasia. Exp Eye Res. 2014;129:172–182.
3. Yousef YA, Finger PT. Squamous carcinoma and dysplasia of the conjunctiva and cornea: an analysis of 101 cases. Ophthalmology. 2012;119(2):233–240. doi:10.1016/j.ophtha.2011.08.005
4. Ip MH, George CR, Naing Z, et al. Topical cidofivir for treatment-refractory ocular surface squamous neoplasia. Ophthalmology. 2018;125(4):617–619. doi:10.1016/j.jjophtha.2017.11.021
5. Gupta A, Muecke J. Treatment of ocular surface squamous neoplasia with Mitomycin C. Br J Ophthalmol. 2010;94:555–558. doi:10.1136/bjo.2009.168294
6. Shields CL, Naseripour M, Shields JA. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol. 2002;133(5):601–606. doi:10.1016/S0002-9394(02)01400-9
7. Kao AA, Galor A, Karp CL, et al. Clinicopathologic correlation of ocular surface neoplasms at Bascom Palmer eye institute: 2001 to 2010. Ophthalmology. 2012;119:1773–1776. doi:10.1016/j.jjophtha.2012.02.049
8. Shousha MA, Karp CL, Canto AP, et al. Diagnosis of ocular surface lesions using ultra-high-resolution optical coherence tomography. Ophthalmology. 2013;120:883–891. doi:10.1016/j.jjophtha.2012.10.025
9. Nanji AA, Sayyad FE, Galor A, et al. High-resolution optical coherence tomography as an adjunctive tool in the diagnosis of corneal and conjunctival pathology. Ocul Surf. 2015;13(3):226–235. doi:10.1016/j.jtos.2015.02.001
10. Midena E, DegliAngeli C, Valenti M, et al. Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol. 2000;84(3):268–272. doi:10.1136/bjo.84.3.268
11. Semenova EA, Milman T, Finger PT, et al. The diagnostic value of exfoliative cytology vs histopathology for ocular surface squamous neoplasia. Am J Ophthalmol. 2009;148:772–778. doi:10.1016/j.ajo.2009.06.015
12. Mittal V, Narang P, Menon V, et al. Primary simple limbal epithelial transplantation along with excisional biopsy in the management of extensive ocular surface squamous neoplasia. Cornea. 2016;35(12):1650–1652. doi:10.1097/ICO.0000000000000953
13. Tunc M, Char DH, Crawford B, et al. Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: analysis of 60 cases. Br J Ophthalmol. 1999;83(1):98–103. doi:10.1136/bjo.83.1.98
14. Shields CL, Demirec H, Marr BP, et al. Chemoradiation with topical mitomycin C prior to resection of extensive squamous cell carcinoma of the conjunctiva. Arch Ophthalmol. 2005;123:109–113. doi:10.1001/archopht.123.1.109
15. Birkholz ES, Goins KM, Sutphin JE, et al. Treatment of ocular surface squamous cell intraepithelial neoplasia with and without mitomycin C. Cornea. 2011;30:37–41. doi:10.1097/ICO.0b013e3181dec560
16. Prabhasawat P, Tarinvorakup P, Tesavibul N, et al. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea. 2005;24(4):443–448. doi:10.1097/01.ico.0000183418.6557.6a
17. Asoklis RS, Damijonaityte A, Butkiene L, et al. Ocular surface reconstruction using amniotic membrane following excision of conjunctival and limbal tumors. Eur J Ophthalmol. 2011;21(5):552–558.
18. Cheng AM, Zhao D, Chen R, et al. Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. Ocul Surf. 2016;14(1):56–63. doi:10.1016/j.jtos.2015.07.003
19. Rudkin AK, Muecke JS. Adjuvant 5-fluorouracil in the treatment of localized ocular surface squamous neoplasia. Br J Ophthalmol. 2011;95:947–950. doi:10.1136/bmj.2010.186171
20. Li AS, Shih CY, Rosen L, et al. Recurrence of ocular surface squamous neoplasia treated with excisional biopsy and cryotherapy. Am J Ophthalmol. 2015;160(2):213–219. doi:10.1016/j.ajo.2014.05.027
21. Barbazetto IA, Lee TC, Abramson DH. Treatment of conjunctival squamous cell carcinoma with photodynamic therapy. Am J Ophthalmol. 2004;138(2):183–189. doi:10.1016/j.ajo.2004.04.007
22. Hanada K, Nishikawa N, Miyokawa N, et al. Long-term outcome of amniotic membrane transplantation combined with mitomycin C for conjunctival reconstruction after ocular surface squamous neoplasia excision. Int Ophthalmol. 2017;37(1):71–78. doi:10.1007/s10792-016-0231-6
23. Bello CM, Pérez AL, Pierra JN. Giant conjunctival squamous cell carcinoma. Treatment with surgery following topical interferon alpha-2b. Arch Soc Esp Oftalmol. 2016;91(4):188–190. doi:10.1016/j.joffsale.2015.12.018
24. Kim HJ, Shields CL, Shah SU, et al. Giant ocular surface squamous neoplasia managed with interferon alpha2b as immunotherapy or immunoreduction. Ophthalmology. 2012;119:938–944. doi:10.1016/j.jjophtha.2011.11.035
25. Nanji AA, Sayyd FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol. 2013;24(4):336–342. doi:10.1097/ICO.0b013e3283622a13
26. Rudkin AK, Dempster L, Muecke JS. Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy. Clin Experiment Ophthalmol. 2015;43(1):20–25. doi:10.1111/cxo.2015.43.issue-1
27. Al-Barrag A, Al-Shaer M, Al-Matary N, et al. 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea. Clin Ophthalmol. 2010;4:801. doi:10.2147/OPTH.S9709
28. Joag MG, Sise A, Murillo JC, et al. Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia. Ophthalmology. 2016;123(7):1442–1448. doi:10.1016/j.jjophtha.2016.02.034
29. Rodriguez M, Yesilirmak N, Chhadva P, et al. High-resolution optical coherence tomography in the differentiation of inflammatory versus non-inflammatory peripheral corneal thinning. Cornea. 2017;36(1):48. doi:10.1097/ICO.0000000000001023
30. Janssens K, Mertens M, Lauwers N, et al. To study and determine the role of anterior segment optical coherence tomography and ultrasound biomicroscopy in corneal and conjunctival tumors. J Ophthalmol. 2016;2016.
31. Chin EK, Cortés DE, Lam A, et al. Anterior segment OCT and confocal microscopy findings in atypical corneal intraepithelial neoplasia. Cornea. 2013;32(6):875–879. doi:10.1097/ICO.0b013e318285cab9
32. Ramasubramanian A, Shields CL, Sinha N, et al. Ocular surface squamous neoplasia after corneal graft. Am J Ophthalmol. 2010;149:62-5.
33. Holcombe DJ, Lee GA. Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia. Am J Ophthalmol. 2006;142:568–571. doi:10.1016/j.ajo.2006.05.058
34. Acharya N, Ramappa R, Thomas RK. Clinical profile of Ocular Surface Squamous Neoplasia: a retrospective case series. J Evol Med Dent Sci. 2016;5(21):1100–1103. doi:10.14260/jems.2016.5.21.17
35. Chaugule SS, Park J, Finger PT. Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: is surgery necessary? Indian J Ophthalmol. 2018;66(1):55. doi:10.4103/ijo.IJO_590_17
36. Bahrami B, Greenwell T, Muecke JS. Long-term outcomes after adjunctive topical 5-fluorouracil or mitomycin-C for the treatment of surgically excised, localized ocular surface squamous neoplasia. Clin Experiment Ophthalmol. 2014;42(4):317–322. doi:10.1111/ceo.2014.42.issue-4
37. Frucht-Pery J, Rosenman Y, Pe’er J. Topical mitomycin-C for partially excised conjunctival squamous cell carcinoma. Ophthalmology. 2002;109(3):548–552. doi:10.1016/S0161-6420(01)00967-8
38. Khokhar S, Soni A, Singh Sethi H, et al. Combined surgery, cryotherapy and mitomycin-C for recurrent ocular surface squamous neoplasia. Cornea. 2002;21:189–191. doi:10.1097/00003226-200203000-00012
39. Palamar M, Kaya E, Egrilmez S, et al. Amniotic membrane transplantation in surgical management of ocular surface squamous neoplasias: long-term results. Eye. 2014;28(9):1131. doi:10.1038/eye.2014.148
40. Jacinto FA, Margo CE. Clinically occult squamous cell carcinoma of conjunctiva after topical immunotherapy for ocular surface squamous neoplasia. Can J Ophthalmol. 2017;52(4):e152–3. doi:10.1016/j.jcjo.2017.01.009
41. Shields CL, Shields JA, Armstrong T. Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy. Am J Ophthalmol. 2001;132(4):576–578. doi:10.1016/S0002-9394(01)01085-6
42. Ozcan A, Esen E, Ciloglu E. Sutureless amniotic membrane transplantation following excision of ocular surface neoplasia. Int J Ophthalmol. 2015;8(3):637.
43. Agraval U, Rundle P, Rennie IG, et al. Fresh frozen amniotic membrane for conjunctival reconstruction after excision of neoplastic and presumed neoplastic conjunctival lesions. Eye. 2017;31(6):884. doi:10.1038/eye.2016.322
44. Meel R, Dhimain R, Sen S, et al. Immunoreduction of locally advanced orbito-conjunctival squamous cell carcinoma with intraorbital interferon alpha-2b injection: a globe saving approach. Clin Experiment Ophthalmol. 2018;46(1):87–88. doi:110.1111/ceo.2018.46.issue-1
45. Parrozzani R, Frizziero L, Trainiti S, et al. Topical 1% 5-fluorouracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study. Br J Ophthalmol. 2017;101(8):1094–1099. doi:10.1136/bjophthalmol-2016-309219